https://www.selleckchem.com/products/SGI-1776.html 0018). Time to retrieval of the BB was not statistically significant between symptomatic and asymptomatic subjects (p=0.12). After adjusting for age and symptoms, the likelihood of visualizing gastric damage among patients who had BBs removed after 12 postingestion hours was 4.5 times that compared with those with BB removal within 12 hours of ingestion. CONCLUSIONS In this study, swallowed BBs posed a risk of damage to the stomach, including a single case of impaction and perforation of the gastric wall. Clinicians may want to consider retrieval within 12 hours of ingestion of gastric BBs. Larger prospective studies to assess risk of injury are needed. BACKGROUND AND AIMS No data appear to have been reported regarding bleeding risk among patients receiving antiplatelet and anticoagulant treatment during EUS-guided biliary drainage (BD) procedures. The aim of this study was to assess whether hemorrhagic adverse events associated with EUS-BD are increased in patients on antiplatelet and anticoagulant treatment. METHODS Patients receiving antiplatelet and/or anticoagulant treatment who underwent EUS-BD were retrospectively enrolled between May 2015 and August 2019. Patients who did not receive antiplatelet and/or anticoagulant treatment (AP/AC) and who underwent EUS-BD in the same period were also enrolled as a control group. RESULTS A total of 195 patients who underwent EUS-BD was enrolled in this study. Among these, 154 patients were allocated to the control group, and 41 patients to AP/AC group. Overall frequency of adverse events did not differ significantly between the control group (16.2%, 25/154) and AC/AP group (17.1%, 6/41; P=0.80). The overall bleeding event rate was 3.6% (7/195) with no significant difference between the 2 groups. No thromboembolic events were observed with or without interruption of antiplatelet and/or anticoagulant agents. According to logistic regression analysis, the use of antiplatelet